Galecto, Inc. Common Stock earnings per share and revenue
On Nov 06, 2025, GLTO reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Lexaria Bioscience Corp. Common Stock
Report Date
Jan 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+47.21%
Anixa Biosciences, Inc.
Report Date
Jan 12, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.09
Surprise
-0.78%
FAQ
What were Galecto, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Galecto, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Galecto, Inc. Common Stock's Q3 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Galecto, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 17, 2026.
What are the forecasts for Galecto, Inc. Common Stock's next earnings report?
Based on 3
analysts, Galecto, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of -- for Q4 2025.